SIOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SIOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Sio Gene Therapies's PEG is 1. Sio Gene Therapies's 5-Year TTM EBITDA Growth Rate is 25. Sio Gene Therapies's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.38. Therefore, the Peter Lynch Fair Value for today is $-9.50.
As of today (2024-05-21), Sio Gene Therapies's share price is $0.478. Sio Gene Therapies's Peter Lynch fair value is $-9.50. Therefore, Sio Gene Therapies's Price to Peter Lynch Fair Value Ratio for today is N/A.
The historical rank and industry rank for Sio Gene Therapies's Peter Lynch Fair Value or its related term are showing as below:
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
The historical data trend for Sio Gene Therapies's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sio Gene Therapies Annual Data | |||||||||||||||||
Trend | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
Peter Lynch Fair Value | Get a 7-Day Free Trial | - | - | - | - | - |
Sio Gene Therapies Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Peter Lynch Fair Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Sio Gene Therapies's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Sio Gene Therapies's Price-to-Peter-Lynch-Fair-Value falls into.
Sio Gene Therapies's Peter Lynch Fair Value for today is calculated as
Peter Lynch Fair Value | = | PEG Ratio | * | 5-Year TTM EBITDA Growth Rate** | * | EPS without NRI (TTM) |
= | 1 | * | 25 | * | -0.38 | |
= | -9.50 |
Sio Gene Therapies's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Sio Gene Therapies (OTCPK:SIOX) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Sio Gene Therapies's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value | = | Share Price | / | Peter Lynch Fair Value |
= | 0.478 | / | -9.50 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sio Gene Therapies's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Parag V Meswani | officer: Chief Commercial Officer | 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036 |
Pavan Cheruvu | officer: Chief Executive Officer | C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Kristiina Md Vuori | director | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
David W. Nassif | officer: Principal Financial Officer | C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583 |
Senthil Vel Sundaram | director | NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
Dexxon Holdings Ltd. | 10 percent owner | 1 DEXCEL STREET, OR AKIVA L3 30600000 |
Andrew Lo | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Svf Investments (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET, LONDON X0 W1K3JP |
Patrick Machado | 10 percent owner | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Qvt Associates Gp Llc | 10 percent owner | 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036 |
Viking Global Performance Llc | 10 percent owner | 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By Marketwired Marketwired • 02-03-2021
By Marketwired Marketwired • 02-04-2021
By GlobeNewswire GlobeNewswire • 10-21-2021
By GuruFocusNews GuruFocusNews • 02-02-2022
By Marketwired Marketwired • 09-23-2021
By Marketwired Marketwired • 05-13-2021
By Don Li2 Don Li2 • 11-12-2021
By Marketwired Marketwired • 04-28-2021
By Marketwired Marketwired • 10-04-2021
By GuruFocusNews GuruFocusNews • 04-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.